28165738|t|A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway
28165738|a|The cytotoxicity of the natural ent-kaurene diterpenoid, oridonin, has been extensively studied. However, the application of oridonin for cancer therapy was hampered primarily by its moderate potency. In this study, a series of oridonin A-ring modified analogues, and their derivatives bearing various substituents on 14-OH position, were designed, synthesized, and evaluated for anticancer efficacy. Some of the derivatives were significantly more potent than oridonin against both drug - sensitive and drug-resistant cancer cells. The most potent compound, 13p, was 200-fold more efficacious than oridonin in MCF-7 cancer cells. Furthermore, 13p induced apoptosis and cell cycle arrest at the G2/M phase. A decrease in mitochondrial membrane potential and an increase in Bax/Bcl-2 ratio, accompanied by activated caspase-3 cleavage, were observed in MCF-7 cells after treatment with 13p, suggesting that the mitochondrial pathway was involved in the 13p -mediated apoptosis. Moreover, 13p significantly inhibited tumor growth in mouse xenograft models and had no observable toxic effect.
28165738	15	34	Anticancer Compound	T109,T121	C0003392
28165738	52	59	Natural	T169	C0205296
28165738	60	68	Oridonin	T109,T121,T123	C0069639
28165738	86	95	Apoptosis	T043	C0162638
28165738	100	117	Cell Cycle Arrest	T043	C1155873
28165738	130	151	Mitochondrial Pathway	T045	C1513340
28165738	156	168	cytotoxicity	T049	C0596402
28165738	176	183	natural	T169	C0205296
28165738	184	207	ent-kaurene diterpenoid	T121	C1254351
28165738	209	217	oridonin	T109,T121,T123	C0069639
28165738	277	285	oridonin	T109,T121,T123	C0069639
28165738	290	304	cancer therapy	T061	C0920425
28165738	335	351	moderate potency	T038	C0678792
28165738	380	388	oridonin	T109,T121,T123	C0069639
28165738	389	437	A-ring modified analogues, and their derivatives	T104	C0002776
28165738	454	484	substituents on 14-OH position	T104	C1254350
28165738	501	512	synthesized	T052	C1883254
28165738	518	527	evaluated	T058	C0220825
28165738	532	542	anticancer	T109,T121	C0003392
28165738	543	551	efficacy	T080	C1280519
28165738	565	576	derivatives	T104	C0243072
28165738	613	621	oridonin	T109,T121,T123	C0069639
28165738	635	639	drug	T121	C1254351
28165738	642	651	sensitive	T169	C0332324
28165738	656	670	drug-resistant	T038	C0013203
28165738	671	683	cancer cells	T025	C0334227
28165738	701	714	compound, 13p	T109,T121	C0003392
28165738	720	728	200-fold	T079	C1254367
28165738	734	745	efficacious	T080	C1280519
28165738	751	759	oridonin	T109,T121,T123	C0069639
28165738	763	781	MCF-7 cancer cells	T025	C0596890
28165738	796	799	13p	T109,T121	C0003392
28165738	808	817	apoptosis	T043	C0162638
28165738	822	839	cell cycle arrest	T043	C1155873
28165738	847	857	G2/M phase	T043	C1517347
28165738	873	905	mitochondrial membrane potential	T043	C1720920
28165738	925	934	Bax/Bcl-2	T116,T123	C0219474
28165738	957	976	activated caspase-3	T116,T126	C4290004
28165738	977	985	cleavage	T044	C0597304
28165738	1004	1015	MCF-7 cells	T025	C0596890
28165738	1022	1031	treatment	T061	C0087111
28165738	1037	1040	13p	T109,T121	C0003392
28165738	1062	1083	mitochondrial pathway	T045	C1513340
28165738	1104	1107	13p	T109,T121	C0003392
28165738	1118	1127	apoptosis	T043	C0162638
28165738	1139	1142	13p	T109,T121	C0003392
28165738	1167	1179	tumor growth	T191	C0598934
28165738	1183	1188	mouse	T015	C0025929
28165738	1189	1205	xenograft models	T050	C1520166
28165738	1214	1240	no observable toxic effect	T184	C0857329